Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced that the FDA has issued a Complete Response Letter (CRL) in response to the Company’s supplemental Biologics License Application (sBLA) for the F8 formulation of tesamorelin